TGTX קצב צמיחת רווח למניה בשנה הנוכחית TG Pharma

Risks associated with the aggressive capture of the US insurance market are creating volatility, yet the year-over-year percentage difference in EPS demonstrates a critical support level for TG Therapeutics, Inc. (TGTX). Profit streams are based on Briumvi sales, while expansion into Europe and the oncology sphere will drive growth. The value of -63.30 expresses the metric's value today, confirming the current earnings per share trend.
פילוחי מדדים מקיפים ואנליטיקה עבור TG Therapeutics (TGTX)

To objectively assess the operational efficiency of TG Therapeutics, Inc. (TGTX), investors must track the actual dynamics of net earnings per share. By analyzing the annual EPS amplitude, you can observe the percentage shift in profitability relative to the previous year, which allows for a measurement of the effectiveness of Michael Weiss's aggressive commercialization strategy and an evaluation of his risky management style through the lens of long-term profit growth.